Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tarsus Pharmaceuticals (TARS) Operating Expenses (2020 - 2025)

Tarsus Pharmaceuticals has reported Operating Expenses over the past 6 years, most recently at $159.6 million for Q4 2025.

  • Quarterly results put Operating Expenses at $159.6 million for Q4 2025, up 75.76% from a year ago — trailing twelve months through Dec 2025 was $522.3 million (up 72.09% YoY), and the annual figure for FY2025 was $522.3 million, up 72.09%.
  • Operating Expenses for Q4 2025 was $159.6 million at Tarsus Pharmaceuticals, up from $133.2 million in the prior quarter.
  • Over the last five years, Operating Expenses for TARS hit a ceiling of $159.6 million in Q4 2025 and a floor of $14.7 million in Q2 2021.
  • Median Operating Expenses over the past 5 years was $37.8 million (2023), compared with a mean of $57.2 million.
  • Biggest five-year swings in Operating Expenses: surged 972.62% in 2021 and later fell 11.7% in 2022.
  • Tarsus Pharmaceuticals' Operating Expenses stood at $14.8 million in 2021, then skyrocketed by 69.49% to $25.1 million in 2022, then skyrocketed by 129.54% to $57.5 million in 2023, then skyrocketed by 57.89% to $90.8 million in 2024, then surged by 75.76% to $159.6 million in 2025.
  • The last three reported values for Operating Expenses were $159.6 million (Q4 2025), $133.2 million (Q3 2025), and $124.8 million (Q2 2025) per Business Quant data.